Calendario›AMGN›ABX-EGF

ABX-EGF

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Ensayo de AMGEN INC en Non-small Cell Lung Cancer · Neoplasm Metastasis · Lung Cancer (del registro, en inglés).

Más ensayos de: Cáncer de pulmón no microcítico · Cáncer de pulmón.

Fase

Fase 2

Estado

Completado

Participantes

50

previstos

Fin del objetivo primario

dic 2004

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en jun 2003.

Qué mide

Objective Tumor Response (End of initial 6 week treatment period) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroRationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis. TGFa and EGF, the ligands for EGFR, are also overexpressed in some of these tumor types, suggesting a self-propagating stimulus that may be responsible for rapid tumor growth. Blocking this stimulus by blocking activation of EGFR with ABX-EGF, a fully human monoclonal antibody against EGFR, may prevent tumor growth and perhaps shrink tumors. Purpose: This is a Phase 2 clinical trial to evaluate the safety and efficacy of ABX-EGF in the treatment of advanced NSCLC following failure of paclitaxel and carboplatin therapy on treatment arm 1 of Immunex Protocol 054.0004 (Amgen Protocol 20025404), Part 2.

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00101920), actualizada en oct 2010.